Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca Buys Amgen’s Biologics Bulk Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

AstraZeneca Buys Amgen’s Biologics Bulk Mfg. Facility

Expands biologics manufacturing capability in the U.S. to support advancing pipeline

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca has purchased a high-tech biologics bulk manufacturing facility from Amgen, expanding its biologics manufacturing capability in the U.S. The LakeCentre facility, located in Boulder, CO will increase production capacity to support its portfolio of biologics.
 
The company will begin staffing the facility to support infrastructure improvements, and it is expected to be operational and licensed for commercial production by late 2017.
 
Down the road, this site could create as many as 400 highly skilled jobs, and will eventually double the biologics manufacturing capacity in the U.S. to accommodate its maturing pipeline. Currently biologics make up 50% of the company’s pipeline with more than 120 ongoing programs, including more than 30 in clinical development.
 
Pam Cheng, executive vice president, Operations and Information Technology at AstraZeneca, said, “The addition of the Boulder facility will support the progression of biotech drug candidates across our main therapeutic areas as we continue to bring innovative new treatments to patients. This site will play an important role in our future commercial production and give AstraZeneca and MedImmune, our global biologics research and development arm, the flexibility and capacity to meet the needs of our rapidly growing biologics portfolio.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics